LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative cell therapy transplanted into patients’ lymph nodes…
Mediwave Wins Global Recognition at GLOMO Awards 2024 for Health Technologies for Emergency Response
Mediwave, a leading health technology company, has been recognized as a finalist in the prestigious Global Mobile Awards (GLOMO), part of the Mobile World Congress (MWC) hosted by the GSMA in Barcelona, Spain. This recognition highlights Mediwave’s outstanding contributions in…
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand…
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of…
Supply & Demand Chain Executive Names Spinnaker SCA’s Leaders as Recipients of 2024’s Prestigious Pros to Know Award for Lifetime Achievement
Supply & Demand Chain Executive, the only publication covering the entire global supply chain, named three of Spinnaker SCA’s executives as Lifetime Achievement recipients. John Sharkey, Chief Executive Officer, George Fowler, Chief Technology Officer and Senior Vice President of Planning and Omnichannel, and Joel Garcia, Senior Vice…
Health technology leader Philips recognized as Clarivate Top 100 Global Innovator
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included in the 2024 Clarivate Top 100 Global Innovator™ list. Philips’ global R&D programs and collaborations aim to deliver personal health solutions for consumers and professional health solutions…
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)…
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™…
China Medical University Hospital’s Breakthrough: Leg Salvage Against Deadly Arterial Disease. Amputation and Death Rates Plunge from 30% to Below 3%
In winter, cardiovascular diseases are more prevalent, which significantly increase the likelihood of arterial blockage. In addition to increasing the possibility of accompanying myocardial infarction or stroke, seniors should be especially cautious about Peripheral Arterial Occlusive Disease (PAOD). In mild…
Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics
Beyond Celiac, the leading catalyst for a cure for celiac disease, today announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and…
